Focal adhesion kinase: An alternative focus for anti-angiogenesis therapy in ovarian cancer

Cancer Biology and Therapy

Volumn 15, Issue 7, 2014, Pages 919-929

  Stone, Rebecca L ^a   Baggerly, Keith A ^a   Armaiz Pena, Guillermo N ^a   Kang, Yu ^b   Sanguino, Angela M ^a   Thanapprapasr, Duangmani ^a   Dalton, Heather J ^a   Bottsford Miller, Justin ^a   Zand, Behrouz ^a   Akbani, Rehan ^a   Diao, Lixia ^a   Nick, Alpa M ^a   DeGeest, Koen ^c   Lopez Berestein, Gabriel ^a   Coleman, Robert L ^a   Lutgendorf, Susan ^d   Sood, Anil K ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b FUDAN UNIVERSITY   (China)

^c UNIVERSITY OF IOWA   (United States)

^d E11 SSH   (United States)

Author keywords

Angiogenesis; Cancer molecular biology; Metastasis; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE INHIBITOR; UNCLASSIFIED DRUG; VS 6062; ANGIOGENESIS INHIBITOR; INDOLE DERIVATIVE; N-METHYL-N-(3-((2-(2-OXO-2,3-DIHYDRO-1H-INDOL-5-YLAMINO)-5-TRIFLUOROMETHYL-PYRIMIDIN-4-YLAMINO)-METHYL)-PYRIDIN-2-YL)-METHANESULFONAMIDE; PROTEIN KINASE INHIBITOR; SULFONAMIDE; TYROSINE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CAPILLARY DENSITY; CELL COMPARTMENTALIZATION; CELL MIGRATION; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; METASTASIS; MOUSE; NONHUMAN; OVARY CARCINOMA; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR GROWTH; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; GENETICS; METABOLISM; NEOPLASMS, GLANDULAR AND EPITHELIAL; NEOVASCULARIZATION, PATHOLOGIC; NUDE MOUSE; OVARIAN NEOPLASMS; PATHOLOGY; PHOSPHORYLATION; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; ENDOTHELIAL CELLS; FEMALE; FOCAL ADHESION PROTEIN-TYROSINE KINASES; GENE DOSAGE; HUMANS; INDOLES; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASMS, GLANDULAR AND EPITHELIAL; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; SULFONAMIDES; TYROSINE;

EID: 84903852837     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.28882     Document Type: Article

References (25)

1. van der Bilt AR, de Vries EG, de Jong S, Timmer-Bosscha H, van der Zee AG, Reyners AK. Turning promise into progress for antiangiogenic agents in epithelial ovarian cancer. Crit Rev Oncol Hematol 2012; 84:224-42; PMID:22525643; http://dx.doi.org/10.1016/j.critrevonc.2012.03.006
2. Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D, Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15:220-31; PMID:19249680; http://dx.doi.org/10. 1016/j.ccr.2009.01.027
3. Cukierman E, Pankov R, Stevens DR, Yamada KM. Taking cell-matrix adhesions to the third dimension. Science 2001; 294:1708-12; PMID:11721053; http://dx.doi.org/10.1126/science.1064829 (Pubitemid 33104840)
4. Chatzizacharias NA, Kouraklis GP, Theocharis SE. Clinical significance of FAK expression in human neoplasia. Histol Histopathol 2008; 23:629-50; PMID:18283648 (Pubitemid 351552349)
5. Mon NN, Ito S, Senga T, Hamaguchi M. FAK signaling in neoplastic disorders: a linkage between inflammation and cancer. Ann N Y Acad Sci 2006; 1086:199-212; PMID:17185517; http://dx.doi.org/10.1196/annals.1377.019 (Pubitemid 47084387)
6. Parsons JT, Martin KH, Slack JK, Taylor JM, Weed SA. Focal adhesion kinase: a regulator of focal adhesion dynamics and cell movement. Oncogene 2000; 19:5606-13; PMID:11114741; http://dx.doi.org/10.1038/sj.onc.1203877
7. McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG, Frame MC. The role of focal-adhesion kinase in cancer-a new therapeutic opportunity. Nat Rev Cancer 2005; 5:505-15; PMID:16069815; http://dx.doi.org/10.1038/nrc1647
8. Angelucci A, Bologna M. Targeting vascular cell migration as a strategy for blocking angiogenesis: the central role of focal adhesion protein tyrosine kinase family. Curr Pharm Des 2007; 13:2129-45; PMID:17627545; http://dx.doi.org/10.2174/138161207781039643 (Pubitemid 47074046)
9. Donninger H, Bonome T, Radonovich M, Pise-Masison CA, Brady J, Shih JH, Barrett JC, Birrer MJ. Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways. Oncogene 2004; 23:8065-77; PMID:15361855; http://dx.doi.org/10.1038/sj.onc.1207959 (Pubitemid 39531847)
10. Sood AK, Coffin JE, Schneider GB, Fletcher MS, DeYoung BR, Gruman LM, Gershenson DM, Schaller MD, Hendrix MJ. Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion. Am J Pathol 2004; 165:1087-95; PMID:15466376; http://dx.doi.org/10.1016/S0002-9440(10)63370- 6 (Pubitemid 39297716)
11. Kiechle M, Jacobsen A, Schwarz-Boeger U, Hedderich J, Pfisterer J, Arnold N. Comparative genomic hybridization detects genetic imbalances in primary ovarian carcinomas as correlated with grade of differentiation. Cancer 2001; 91:534-40; PMID:11169935; http://dx.doi.org/10.1002/1097-0142(20010201)91: 3<534::AIDCNCR1031> 3.0.CO;2-T (Pubitemid 32105698)
12. Hauptmann S, Denkert C, Koch I, Petersen S, Schlüns K, Reles A, Dietel M, Petersen I. Genetic alterations in epithelial ovarian tumors analyzed by comparative genomic hybridization. Hum Pathol 2002; 33:632-41; PMID:12152163; http://dx.doi.org/10.1053/hupa.2002.124913 (Pubitemid 34827545)
13. Golubovskaya VM, Nyberg C, Zheng M, Kweh F, Magis A, Ostrov D, Cance WG. A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth. J Med Chem 2008; 51:7405-16; PMID:18989950; http://dx.doi.org/10.1021/jm800483v
14. Roberts WG, Ung E, Whalen P, Cooper B, Hulford C, Autry C, Richter D, Emerson E, Lin J, Kath J, et al. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res 2008; 68:1935-44; PMID:18339875; http://dx.doi.org/10.1158/0008-5472.CAN-07-5155 (Pubitemid 351416580)
15. Slack-Davis JK, Martin KH, Tilghman RW, Iwanicki M, Ung EJ, Autry C, Luzzio MJ, Cooper B, Kath JC, Roberts WG, et al. Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem 2007; 282:14845-52; PMID:17395594; http://dx.doi.org/10.1074/jbc.M606695200 (Pubitemid 47093369)
16. Schultze A, Fiedler W. Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer. Expert Opin Investig Drugs 2010; 19:777-88; PMID:20465362; http://dx.doi.org/10.1517/135437 84.2010.489548
17. Jones SF, Moore KN, Patel MR, Infante JR, Poli A, Keegan M, Burris HA. A phase I/IB study of paclitaxel in combination with VS-6063, a focal adhesion kinase (FAK) inhibitor, in patients (pts) with advanced ovarian cancer. J Clin Oncol [Online] 2013; suppl; abstr TPS2620. Available from: http:// meetinglibrary.asco.org/content/117259-132
18. Hirt U, Schleicher M, et al. BI 853520, a potent and highly selective inhibitor of protein tyrosine kinase 2 (focal adhesion kinase), shows efficacy in multiple xenograft models of human cancer. Mol Can Ther 2011; 10; http://dx.doi.org/10.1158/1535-7163. TARG-11-A249.
19. Golubovskaya VM. Targeting FAK in human cancer: from finding to first clinical trials. Front Biosci (Landmark Ed) 2014; 19:687-706; PMID:24389213; http://dx.doi.org/10.2741/4236
20. Shen TL, Park AY, Alcaraz A, Peng X, Jang I, Koni P, Flavell RA, Gu H, Guan JL. Conditional knockout of focal adhesion kinase in endothelial cells reveals its role in angiogenesis and vascular development in late embryogenesis. J Cell Biol 2005; 169:941-52; PMID:15967814; http://dx.doi.org/10.1083/jcb. 200411155 (Pubitemid 41002870)
21. Tavora B, Batista S, Reynolds LE, Jadeja S, Robinson S, Kostourou V, Hart I, Fruttiger M, Parsons M, Hodivala-Dilke KM. Endothelial FAK is required for tumour angiogenesis. EMBO Mol Med 2010; 2:516-28; PMID:21154724; http://dx.doi.org/10.1002/emmm.201000106
22. Gadducci A, Ferrero A, Cosio S, Zola P, Viacava P, Dompé D, Fanelli G, Ravarino N, Motta M, Cristofani R, et al. Intratumoral microvessel density in advanced epithelial ovarian cancer and its use as a prognostic variable. Anticancer Res 2006; 26(5B):3925-32; PMID:17094423 (Pubitemid 44701480)
23. Palmer JE, Sant Cassia LJ, Irwin CJ, Morris AG, Rollason TP. Prognostic value of measurements of angiogenesis in serous carcinoma of the ovary. Int J Gynecol Pathol 2007; 26:395-403; PMID:17885489; http://dx.doi.org/10.1097/pgp. 0b013e318063bed7 (Pubitemid 47476324)
24. Agochiya M, Brunton VG, Owens DW, Parkinson EK, Paraskeva C, Keith WN, Frame MC. Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells. Oncogene 1999; 18:5646-53; PMID:10523844; http://dx.doi.org/10.1038/sj.onc.1202957 (Pubitemid 29497599)
25. Golubovskaya V, Kaur A, Cance W. Cloning and characterization of the promoter region of human focal adhesion kinase gene: nuclear factor kappa B and p53 binding sites. Biochim Biophys Acta 2004; 1678:111-25; PMID:15157737; http://dx.doi.org/10.1016/j.bbaexp.2004.03.002 (Pubitemid 38626172)